Abstract: The core treatment goal for glaucoma is reducing intraocular pressure. Traditional intraocular pressure -lowering medications are commonly administered as monotherapy or in combination. However, combination therapy often increases treatment complexity, leading to reduced patient adherence and diminished efficacy. Fixed-dose combinations (FDCs) simplify treatment regimens by integrating multiple intraocular pressure-lowering drugs into a single formulation. Studies have shown that FDCs significantly improve adherence compared to non-FDC regimens. Furthermore, the efficacy of FDCs in reducing intraocular pressure is at least non-inferior to non-FDC combinations. Additionally, preservative-free FDCs minimize ocular surface disease caused by preservatives, reducing conjunctival hyperemia rates, significantly improving tolerability. The adoption of FDCs not only optimizes therapeutic outcomes but also alleviates economic burdens, offering a superior treatment option for glaucoma patients. (Int Rev Ophthalmol, 2025, 49:  88-94)

Key words: glaucoma, intraocular pressure, fixed-dose combination (FDC)